Preclinical publications
Papers and presentations from the Preclinical program.
All publications and presentations
- PresentationTherapeutic benefits of MSC-NTF (NurOwn®) exosomes in acute lung injury models 2021 NYSCF Conference View source
- Peer-reviewedMSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model Stem Cell Research & Therapy View source
- Peer-reviewedmiRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors Stem Cell Research & Therapy View source
- Peer-reviewedLong term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism Behavioural Brain Research View source
- Peer-reviewedConcise review: mesenchymal stem cells in neurodegenerative diseases Stem Cells View source
- Peer-reviewedIntravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection Invest Ophthalmol Vis Sci View source
- Peer-reviewedProtective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease Stem Cells and Development View source
- Peer-reviewedAdult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases Isr Med Assoc J View source
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.